Dr Umberto Capitanio from the Department of Urology, San Raffaele Scientific Institute, Milan, Italy, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

In the United States, sunitinib (Sutent) is now approved for the adjuvant treatment of this population. In Europe however, guidelines do not recommend the use of adjuvant therapy due to conflicting published results.

See Dr Umberto’s short video here